Gehts schon wieder los? - 500 Beiträge pro Seite

[Frontliners]

Die Aktie schiesst gerade nach dem Split und heftigen Einbrüchen, aktuell um 80% nach oben. Denke mal ist auf diesen News zurückzuführen. -> http://www.prnewswire.com/news-releases/interpace-diagnostic…

Wie deutet ihr den Deal? Geht es in den nächsten Tagen weiter nach oben?

[Frontliners]

Jetzt haben wir schon 150% drüben

[curacanne]

Antwort auf Beitrag Nr.: 54.000.440 von Frontliners am 03.01.17 16:59:29

was das denn für eine g.... aktie
bist Du dabei?

[Zohan1]

[Zohan1]

bin jetzt wieder dabei

[Zohan1]

geht Heute was bei der Nachricht?

Back YahooFINANCE Share
Interpace Diagnostics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement

PR Newswire PR NewswireJanuary 17, 2017
PARSIPPANY, N.J., Jan. 17, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc., (IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risks of cancer, announced today that it has received a letter dated January 13, 2017 from the NASDAQ Listing Qualifications notifying the Company that it has regained compliance with the requirement of the NASDAQ Stock Market to maintain a minimum closing bid price of $1.00 per share.
The letter noted that for the last 10 days from December 29, 2016 to January 12, 2017, the closing bid price of the Company's common stock has been at $1.00 or greater. Accordingly, NASDAQ informed the Company that it has regained compliance with Listing Rule 5550(a)(2) and that the matter was now closed.

Separately, the Company has submitted a plan to NASDAQ to regain compliance with the NASDAQ stockholder equity requirement of $2.5 Million.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

[Zohan1]

Interpace Diagnostics Announces New Partnership with Israeli Specialty Services Provider

Yahoo Finance's ALL MARKETS SUMMIT
Interpace Diagnostics Announces New Partnership with Israeli Specialty Services Provider

PR Newswire PR NewswireJanuary 20, 2017
PARSIPPANY, N.J., Jan. 20, 2017 /PRNewswire/ -- Interpace Diagnostics Corp. ("Interpace" or the "Company") (IDXG), a company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risks of cancer, announced today that the Company has entered in to an Agreement (the "Agreement") with Best Med Opinion Ltd ("Best Med") of Tel Aviv, Israel, a provider of second opinion and clinical services for physicians and patients in Israel and several other countries.